Drugs / CSL360
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00401739 | Dec 2006 → Sep 2009 | acute myeloid leukemia | CSL Limited | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CSL360 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00401739 ↗ |
| Action | Inhibit | “Interleukin-3 receptor subunit alpha inhibitor” CHEMBL2109327 ↗1“CSL360 is a neutralising monoclonal antibody” NCT00401739 ↗ |
| Target | IL3RA | “Interleukin-3 receptor subunit alpha inhibitor” CHEMBL2109327 ↗ |